Wedbush Reiterates Outperform on Quanex (NX) Following 2Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Imperial Capital Reiterates Outperform on Quanex (NX) Following 2Q Earnings Report
June 2, 2016 7:16 AM EDTImperial Capital maintained an Outperform rating and $25.00 price target on Quanex Building Products (NYSE: NX) following the company's 2Q earnings report. Adjusted EPS of $0.10 for 2Q16 exceeded the consensus estimate of $0.08. Revenue exceeded Imperial's estimate by $5.5mn.
Analyst Scott Levine commented, "We are... More
After-Hours Stock Movers 05/31: (ZOES) (BYD) (SRPT) Higher; (ADPT) (ASNA) (UA) (BABA) Lower (more...)
May 31, 2016 5:55 PM EDTToday's After-Hours Movers:
Adeptus Health Inc. (NYSE: ADPT) 8.3% LOWER; announced the offering of 2,750,000 shares of its Class A common stock, of which 1,843,162 shares are to be sold by the Company, and 906,838 shares are to be sold by an affiliate of Sterling Partners (the "Selling Stockholder"). The Company intends to use all of the net proceeds from the offering received by it to purchase, for cash, 1,843,162 limited liability company units of Adeptus Health LLC, its direct subsidiary, from certain of the unit holders of Adeptus Health LLC, including... More
Quanex (NX) Tops Q2 EPS by 1c, Updates FY Guidance
May 31, 2016 4:21 PM EDTQuanex (NYSE: NX) reported Q2 EPS of $0.10, $0.01 better than the analyst estimate of $0.09. Revenue for the quarter came in at $229.5 million versus the consensus estimate of $228.86 million.
GUIDANCE:
Quanex sees FY2016 EPS of $0.78-$0.87, versus the consensus of $0.83. Quanex sees... More
